Drugs / PP 1420
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01052493 | Apr → Oct 2010 | obesity disorder | Imperial College London | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02221765 | Aug 2014 → May 2016 | obesity disorder | Imperial College London | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PP 1420 | “We have developed a new long lasting high potency analogue of PP, PP1420.” NCT02221765 ↗ |
| Modality | Peptide | “novel analogue of human pancreatic polypeptide, PP 1420” PMID 21834938 ↗ Feb 2012 |
| Route | Subcutaneous | “administered subcutaneously at either 2mg, 4mg or 8mg.” NCT01052493 ↗ |